• Exelixis Inc., of South San Francisco, started METEOR, a Phase III pivotal trial comparing cabozantinib to everolimus (Afinitor, Novartis) in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor. The primary endpoint for the trial is progression-free survival.